Balancing the interests of the applicants and the public, China has imposed strict restrictions on the examination of supplementary experimental data.
This is a preview of subscription content, log in via an institution to check access.
References
Patent Reexamination Board patent invalidation decision no. 34432 (China National Intellectual Property Administration, 2018).
Liu, M. & Zheng C. Examination criteria for supplementing experimental data in the patent application for biomedical products. China Intellectual Property News (February 2017).
Zhang, Q. Review and prospect on the focus during patent examination of chemical and pharmaceutical inventions—about the request and supplementary for experimental data. China Invention & Patent 8, 13–20 (2018).
Dong, H. Examination criteria for supplementary experimental data after the date of application. China Intellectual Property News (May 2018).
China Patent Law, Article 26.3 (2009).
China Patent Law, Article 22.3 (2009).
Supreme People’s Court. SPC XS No. 1878 Administrative Ruling (2016).
Supreme People’s Court. ZXZ No. 41 Administrative Ruling (2012).
Liu, M. Consideration and standard construction of supplementary experimental data in biomedical field—from the perspective of creativity. Sci. Technol. Law 5, 16–22 (2017).
Supreme People’s Court. XTZ No. 8 Administrative Ruling (2016).
Beijing Municipal High People’s Court (2017) JXZ No. 1642 Administrative Ruling (2017).
Beijing Municipal High People’s Court (2017) JXZ No. 1806 Administrative Ruling (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Li, W. Analysis of the standard for accepting supplementary experimental data in China’s patent practice. Nat Biotechnol 38, 27–29 (2020). https://doi.org/10.1038/s41587-019-0365-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-019-0365-y
- Springer Nature America, Inc.